{"id":1415,"date":"2024-04-21T12:30:54","date_gmt":"2024-04-21T16:30:54","guid":{"rendered":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/?p=1415"},"modified":"2024-04-21T12:30:54","modified_gmt":"2024-04-21T16:30:54","slug":"new-cancer-vaccine-harnesses-the-human-immune-system","status":"publish","type":"post","link":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/science\/new-cancer-vaccine-harnesses-the-human-immune-system\/","title":{"rendered":"New Cancer Vaccine Harnesses the Human Immune System"},"content":{"rendered":"<p><span style=\"font-weight: 400\">Right now, cancer is the second most common cause of death in the world, and it\u2019s set to become the leading cause within the next several decades (Drexler) (Figure 1). Unlike many other diseases that have plagued humans throughout our history, even revolutionary advancements in medicine have not been able to fully prevent or cure it. To understand why, it\u2019s important to recognize that cancer comes not from the outside, but from within ourselves, when our own cells begin to divide uncontrollably and spread throughout our bodies. Because cancer arises in our bodies, we can\u2019t treat it using antibiotics or vaccines that target a particular pathogen. However, a 2023 study has proposed a new vaccine treatment that fights pancreatic cancer (which has a five-year survival rate of only 12%) using our own immune system.<\/span><\/p>\n<figure id=\"attachment_1434\" aria-describedby=\"caption-attachment-1434\" style=\"width: 438px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-1434 \" src=\"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-content\/uploads\/sites\/35\/2024\/04\/db254_fig1-300x222.png\" alt=\"\" width=\"438\" height=\"324\" srcset=\"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-content\/uploads\/sites\/35\/2024\/04\/db254_fig1-300x222.png 300w, https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-content\/uploads\/sites\/35\/2024\/04\/db254_fig1-768x567.png 768w, https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-content\/uploads\/sites\/35\/2024\/04\/db254_fig1.png 960w\" sizes=\"auto, (max-width: 438px) 100vw, 438px\" \/><figcaption id=\"caption-attachment-1434\" class=\"wp-caption-text\">Figure 1. Cancer deaths are expected to surpass deaths due to heart disease in the United States. Source: CDC<\/figcaption><\/figure>\n<p><span style=\"font-weight: 400\">To understand this discovery, it\u2019s important to learn a little about how the immune system works. One important component of our body\u2019s defense system are our T cells, which fight invaders by identifying and killing body cells infected with pathogens such as viruses. A T cell only knows what to attack after it\u2019s activated by a foreign particle called an antigen. Antigens are often tiny pieces of invading viruses or bacteria, like \u201ckeys\u201d which unlock a T cell immune response. Now, what does all this have to do with cancer? The idea behind this proposed treatment is to use neoantigens (a type of antigen) to help the body recognize cancer cells. Neoantigens are mutant proteins which only form on tumor cells, so helping T cells recognize them could help the body learn to attack cancerous cells.<\/span><\/p>\n<figure id=\"attachment_1433\" aria-describedby=\"caption-attachment-1433\" style=\"width: 340px\" class=\"wp-caption alignleft\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-1433 \" src=\"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-content\/uploads\/sites\/35\/2024\/04\/mRNA-vaccine-pancreatic-cancer-290x300.jpeg\" alt=\"\" width=\"340\" height=\"352\" srcset=\"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-content\/uploads\/sites\/35\/2024\/04\/mRNA-vaccine-pancreatic-cancer-290x300.jpeg 290w, https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-content\/uploads\/sites\/35\/2024\/04\/mRNA-vaccine-pancreatic-cancer.jpeg 423w\" sizes=\"auto, (max-width: 340px) 100vw, 340px\" \/><figcaption id=\"caption-attachment-1433\" class=\"wp-caption-text\">Figure 2. In combination with ICI treatment, these novel mRNA vaccines prompt the immune system to attack cancer cells by manufacturing the neoantigens on their surface. Adapted from Huff &amp; Zaidi (2023) and created with BioRender.com.<\/figcaption><\/figure>\n<p><span style=\"font-weight: 400\">This study\u2019s major discovery was a new way to prompt the immune system to recognize neoantigens. The researchers took genetic material (such as DNA and RNA) from the surgically removed tumors of sixteen people with pancreatic cancer. Then they gave each patient a kind of treatment called an immune-<\/span><span style=\"font-weight: 400\">checkpoint inhibitor (ICI). Immune checkpoints are proteins on the surfaces of healthy cells which usually tell our T cells not to attack them. The problem is that sometimes, immune checkpoints on cancerous cells prevent T cells from attacking them too. ICIs can treat some kinds of cancers by blocking these interactions between T cells and cancerous cells, allowing T cells to kill them, but they often do not work well on pancreatic cancer. To solve this problem, the researchers used the genetic information collected from the tumors to create a personalized vaccine containing mRNA (a type of RNA) that codes for the exact neoantigen formed on an individual\u2019s cancer cells. After receiving this vaccine, a person\u2019s cells would be able to use the mRNA to produce this neoantigen in abundance. Then, their T cells could theoretically recognize it, become activated, and know to go after the cancer cells with the neoantigen on their surfaces (Figure 2). To maximize the chances of triggering this T cell response, the vaccines included mRNA coding for as many as twenty neoantigens.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Now for the big question: did it work? Well, cancer unfortunately came back an average of 13.4 months after treatment for half of the study\u2019s participants. The other eight, however, all had T cells which recognized the artificial neoantigens in their bodies after vaccine treatment and also remained cancer-free after ~18 months (Huff &amp; Zaidi, 2023). This vaccine is clearly not perfect, and future research is still needed to understand why half the patients\u2019 immune systems did not respond to the treatment. However, it is still an incredible breakthrough that could shift the direction of cancer treatment. A clinical trial, the second phase of this study, is already well underway and includes over 250 patients (Stallard, 2024). Given the small sample size of this first study, the new clinical trial will help clarify how effective this vaccine treatment really is. Immunotherapy is emerging as a leading factor in the fight against cancer, and this study gives reason to believe that new treatment possibilities could be on the horizon for cancer patients, even those with aggressive tumors.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><b>References<\/b><\/p>\n<p><span style=\"font-weight: 400\">Drexler, M. (n.d.). <\/span><i><span style=\"font-weight: 400\">The Cancer Miracle Isn\u2019t a Cure. It\u2019s Prevention.<\/span><\/i><span style=\"font-weight: 400\"> Harvard Public Health. <\/span><a href=\"https:\/\/www.hsph.harvard.edu\/magazine\/magazine_article\/the-cancer-miracle-isnt-a-cure-its-prevention\/\"><span style=\"font-weight: 400\">https:\/\/www.hsph.harvard.edu\/magazine\/magazine_article\/the-cancer-miracle-isnt-a-cure-its-prevention\/<\/span><\/a><span style=\"font-weight: 400\">.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">Heron, M. &amp; Anderson, R.N. (2016). Changes in the leading cause of death: Recent patterns in heart disease and cancer mortality. <\/span><i><span style=\"font-weight: 400\">CDC: NCHS data brief, 254.<\/span><\/i> <a href=\"https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db254.htm\"><span style=\"font-weight: 400\">https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db254.htm<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Huff, A.L. &amp; Zaidi, N. (2023, May 10). <\/span><i><span style=\"font-weight: 400\">Vaccine boosts T cells that target pancreatic tumours.<\/span><\/i><span style=\"font-weight: 400\"> Nature. <\/span><a href=\"https:\/\/www.nature.com\/articles\/d41586-023-01526-8\"><span style=\"font-weight: 400\">https:\/\/www.nature.com\/articles\/d41586-023-01526-8<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Rojas, L.A., Sethna, Z., Soares, K.C. et al. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. <\/span><i><span style=\"font-weight: 400\">Nature 618<\/span><\/i><span style=\"font-weight: 400\">, 144\u2013150. <\/span><a href=\"https:\/\/doi.org\/10.1038\/s41586-023-06063-y\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1038\/s41586-023-06063-y<\/span><\/a><span style=\"font-weight: 400\">.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">Stallard, J. (2024, April 7).<\/span><i><span style=\"font-weight: 400\"> Investigational mRNA Vaccine Induced Persistent Immune Response in Phase 1 Trial of Patients With Pancreatic Cancer<\/span><\/i><span style=\"font-weight: 400\">. Memorial Sloan Kettering Cancer Center. <\/span><a href=\"https:\/\/www.mskcc.org\/news\/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out\"><span style=\"font-weight: 400\">https:\/\/www.mskcc.org\/news\/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Right now, cancer is the second most common cause of death in the world, and it\u2019s set to become the leading cause within the next several decades (Drexler) (Figure 1). Unlike many other diseases that have plagued humans throughout our history, even revolutionary advancements in medicine have not been able to fully prevent or cure [&hellip;]<\/p>\n","protected":false},"author":659,"featured_media":1433,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[63,1],"tags":[],"class_list":["post-1415","post","type-post","status-publish","format-standard","has-post-thumbnail","category-biology","category-science","entry"],"featured_image_src":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-content\/uploads\/sites\/35\/2024\/04\/mRNA-vaccine-pancreatic-cancer-423x400.jpeg","featured_image_src_square":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-content\/uploads\/sites\/35\/2024\/04\/mRNA-vaccine-pancreatic-cancer.jpeg","author_info":{"display_name":"Olivia Miller '27","author_link":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/author\/omiller\/"},"_links":{"self":[{"href":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-json\/wp\/v2\/posts\/1415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-json\/wp\/v2\/users\/659"}],"replies":[{"embeddable":true,"href":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-json\/wp\/v2\/comments?post=1415"}],"version-history":[{"count":0,"href":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-json\/wp\/v2\/posts\/1415\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-json\/wp\/v2\/media\/1433"}],"wp:attachment":[{"href":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-json\/wp\/v2\/media?parent=1415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-json\/wp\/v2\/categories?post=1415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/students.bowdoin.edu\/bowdoin-science-journal\/wp-json\/wp\/v2\/tags?post=1415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}